更多栏目
搜索
113
文章数
14274
浏览数
储旻华

热衷收罗医药圈从研发到上市的各种“八卦”,然后基于事实和数据加以分析

China Biotech Fundraising Tracker: Apr 2021
储旻华 · 15小时以前
Investors Pursuing More Opportunities With mRNA Technology.
Further information
PharmaDJ
China Regulation Tracker: Apr 2021
储旻华 · 15小时以前
The COVID-19 Pandemic Sparks New Healthcare Reform Measures in China.
Further information
PharmaDJ
China Licensing Deals Tracker: Apr 2021
储旻华 · 2021-06-10
CANbridge Secures Two In-Licensing Deals for Rare Disease Therapies.
Further information
PharmaDJ
China Market Approval Tracker: Apr 2021
储旻华 · 2021-06-10
NMPA Expands Three PD-1(L1) Antibodies to Key Patient Populations in China.
Further information
PharmaDJ
肺癌研究谁领风骚 | ASCO 2021
储旻华 · 2021-06-04
关于EGFR-TKI、PD-1(L1)的重要研究。
Further information
其他
CFO视角看创新估值 | 第一现场
储旻华 · 2021-05-23
如何让投资人愿意持续买单?
Further information
第一现场
China Biotech Fundraising Tracker: Mar 2021
储旻华 · 2021-05-19
AffaMed and Brii Bio Rake in Massive Series B and Series C Investments.
Further information
PharmaDJ
China Regulations Tracker: Mar 2021
储旻华 · 2021-05-14
Leaders Endorse Volume-Based Procurement at China's Annual "Two Sessions"
Further information
PharmaDJ
China Licensing Deals Tracker: Mar 2021
储旻华 · 2021-05-13
In-Licensing Deals Bring New Acid Reflux and Ophthalmic Treatments in to China
Further information
PharmaDJ
China Market Approval Tracker: Mar 2021
储旻华 · 2021-05-12
New Cancer & SLE Drugs Gain Market Approval in China
Further information
PharmaDJ
加载更多

个人信息

电子邮箱

chu.minhua@pharmadj.com

公司

研发客

职位

研究院院长

Copyright © 2016-2021 研发客.All Rights Reserved.   建议反馈: Support@PharmaDJ.com   备案/许可证编号:沪ICP备17054709号-1   联系电话:021 - 88194359
关于研发客 | 加入会员 | 联系我们| 知识产权声明